Product/Composition:- | Glipizide ER Tablets |
---|---|
Strength:- | 2.5 mg, 5 mg, 10 mg |
Form:- | ER Tablets |
Reference Brands:- | Glucotrol XL(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Glipizide ER tablets stimulate insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, enhancing postprandial and basal glucose control. The extended-release formulation offers steady drug levels, reduced dosing frequency, and minimized peaks, helping lower the risk of hypoglycemia while effectively managing type 2 diabetes. Ideal for once-daily use.
Glipizide ER tablets are FDA-approved in the USA for managing type 2 diabetes mellitus, helping patients achieve improved glycemic control. Marketed under brands like Glucotrol XL, the ER formulation allows once-daily dosing with steady plasma levels. In the European Union, availability varies by country, and while not as widespread, glipizide ER is recognized under specific regulatory pathways. EU regulators emphasize cardiovascular safety and monitoring of hypoglycemia risk. Manufacturers must comply with pharmacovigilance, GMP, and labeling standards. For B2B bulk sourcing, compliant and vetted suppliers can be accessed through platforms like Pharmatradz.com, supporting global regulatory demands.